Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden, Timothy S. Bailey, Liana K. Billings, et al.
JAMA (2021) Vol. 325, Iss. 14, pp. 1403-1403
Open Access | Times Cited: 623

Showing 1-25 of 623 citing articles:

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2023) Vol. 147, Iss. 8
Open Access | Times Cited: 4195
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 3, pp. 205-216
Open Access | Times Cited: 1714
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 882
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 651
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica Rubino, Frank L. Greenway, Usman Khalid, et al.
JAMA (2022) Vol. 327, Iss. 2, pp. 138-138
Open Access | Times Cited: 580
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 514-526
Closed Access | Times Cited: 468
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2083-2091
Open Access | Times Cited: 415
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 376
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, et al.
The Lancet (2021) Vol. 399, Iss. 10322, pp. 394-405
Closed Access | Times Cited: 368
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 317
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 274
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 253
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Qingyang Shi, Yang Wang, Qiukui Hao, et al.
The Lancet (2021) Vol. 399, Iss. 10321, pp. 259-269
Closed Access | Times Cited: 238
Obesity Management in Adults
Arielle Elmaleh-Sachs, Jessica L. Schwartz, Carolyn T. Bramante, et al.
JAMA (2023) Vol. 330, Iss. 20, pp. 2000-2000
Open Access | Times Cited: 226
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Lone B Enebo, Kasper K. Berthelsen, Martin Kankam, et al.
The Lancet (2021) Vol. 397, Iss. 10286, pp. 1736-1748
Closed Access | Times Cited: 221
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
Susan L. Samson, Priyathama Vellanki, Lawrence Blonde, et al.
Endocrine Practice (2023) Vol. 29, Iss. 5, pp. 305-340
Open Access | Times Cited: 203
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Takashi Kadowaki, Joakim Isendahl, Usman Khalid, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 3, pp. 193-206
Closed Access | Times Cited: 185
Clinical management and treatment of obesity in China
Qiang Zeng, Naishi Li, Xiong‐Fei Pan, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 6, pp. 393-405
Closed Access | Times Cited: 172
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
Francisco López-Jiménez, Wael Almahmeed, Harold Bays, et al.
European Journal of Preventive Cardiology (2022) Vol. 29, Iss. 17, pp. 2218-2237
Open Access | Times Cited: 171
International Consensus Statement on Obstructive Sleep Apnea
Jolie L. Chang, Andrew N. Goldberg, Jeremiah A. Alt, et al.
International Forum of Allergy & Rhinology (2022) Vol. 13, Iss. 7, pp. 1061-1482
Open Access | Times Cited: 164
Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants
Nicholas Syn, David E. Cummings, Louis Z Wang, et al.
The Lancet (2021) Vol. 397, Iss. 10287, pp. 1830-1841
Closed Access | Times Cited: 162
Page 1 - Next Page

Scroll to top